Endologix/TriVascular Tout Breadth Of AAA Indications Offered By Combined Firm
This article was originally published in The Gray Sheet
Endologix will acquire TriVascular Technologies in a $211 million deal expected to close in January. Company execs say they will now be better prepared to go up against larger players in the abdominal aortic aneurysm endovascular device space, offering the broadest set of AAA indications on the market.
Register for our free email digests: